Genta, Inc.

Company acquires c-myb antisense drug from Temple University

Published in Pharma Law Weekly, January 11th, 2005

Genta, Inc., (GNTA) announced that it has acquired worldwide rights from Temple University to intellectual property and technology, and a novel antisense compound (LR3001) that targets c-myb, a central gene that regulates the growth of cancer cells.

LR3001 was developed at Temple and has been tested in two phase I clinical trials at the University of Pennsylvania in patients with drug-resistant myeloid leukemia.

To date, clinical investigations have been supported by grants from the U.S. National Institutes of Health, including the Rapid Access to Investigational Drugs program. A request for designation of LR3001 as an orphan drug for the treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry